These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 37528644)

  • 41. TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis.
    de Anta JM; Jassem E; Rosell R; Martínez-Roca M; Jassem J; Martínez-López E; Monzó M; Sánchez-Hernández JJ; Moreno I; Sánchez-Céspedes M
    Oncogene; 1997 Dec; 15(24):2951-8. PubMed ID: 9416838
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Association between Mutation and Expression of
    Kim JY; Park K; Jung HH; Lee E; Cho EY; Lee KH; Bae SY; Lee SK; Kim SW; Lee JE; Nam SJ; Ahn JS; Im YH; Park YH
    Cancer Res Treat; 2016 Oct; 48(4):1338-1350. PubMed ID: 26910472
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Significance of
    Chen Y; Zhao W; Bi F; Pan X; Yin L; Zhao C
    Oxid Med Cell Longev; 2022; 2022():1817339. PubMed ID: 35847579
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses.
    Kang EY; Cheasley D; LePage C; Wakefield MJ; da Cunha Torres M; Rowley S; Salazar C; Xing Z; Allan P; Bowtell DDL; Mes-Masson AM; Provencher DM; Rahimi K; Kelemen LE; Fasching PA; Doherty JA; Goodman MT; Goode EL; Deen S; Pharoah PDP; Brenton JD; Sieh W; Mateoiu C; Sundfeldt K; Cook LS; Le ND; Anglesio MS; Gilks CB; Huntsman DG; Kennedy CJ; Traficante N; ; DeFazio A; Kaufmann S; Churchman M; Gourley C; Stephens AN; Meagher NS; Ramus SJ; Antill YC; Campbell I; Scott CL; Köbel M; Gorringe KL;
    Mod Pathol; 2021 Jan; 34(1):194-206. PubMed ID: 32724153
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Allelic loss at TP53 is not related to p53 protein overexpression in primary human endometrial carcinomas.
    Semczuk A; Marzec B; Skomra D; Roessner A; Cybulski M; Rechberger T; Schneider-Stock R
    Oncology; 2005; 69(4):317-25. PubMed ID: 16293976
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencing.
    Cole AJ; Dwight T; Gill AJ; Dickson KA; Zhu Y; Clarkson A; Gard GB; Maidens J; Valmadre S; Clifton-Bligh R; Marsh DJ
    Sci Rep; 2016 May; 6():26191. PubMed ID: 27189670
    [TBL] [Abstract][Full Text] [Related]  

  • 47. TP53 protein expression analysis by luminometric immunoassay in comparison with gene mutation status and prognostic factors in early stage endometrial cancer.
    Koul A; Bendahl PO; Borg A; Fernö M; Lidebring MF; Högberg T; Einarsson EL; Ridderheim M; Willén R
    Int J Gynecol Cancer; 2002; 12(4):362-71. PubMed ID: 12144684
    [TBL] [Abstract][Full Text] [Related]  

  • 48. P53 mutation analysis of colorectal liver metastases: relation to actual survival, angiogenic status, and p53 overexpression.
    de Jong KP; Gouw AS; Peeters PM; Bulthuis M; Menkema L; Porte RJ; Slooff MJ; van Goor H; van den Berg A
    Clin Cancer Res; 2005 Jun; 11(11):4067-73. PubMed ID: 15930341
    [TBL] [Abstract][Full Text] [Related]  

  • 49. TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.
    Fountzilas G; Giannoulatou E; Alexopoulou Z; Zagouri F; Timotheadou E; Papadopoulou K; Lakis S; Bobos M; Poulios C; Sotiropoulou M; Lyberopoulou A; Gogas H; Pentheroudakis G; Pectasides D; Koutras A; Christodoulou C; Papandreou C; Samantas E; Papakostas P; Kosmidis P; Bafaloukos D; Karanikiotis C; Dimopoulos MA; Kotoula V
    Oncotarget; 2016 May; 7(22):32731-53. PubMed ID: 27129168
    [TBL] [Abstract][Full Text] [Related]  

  • 50. p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer.
    Bouzourene H; Gervaz P; Cerottini JP; Benhattar J; Chaubert P; Saraga E; Pampallona S; Bosman FT; Givel JC
    Eur J Cancer; 2000 May; 36(8):1008-15. PubMed ID: 10885605
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry.
    Sjögren S; Inganäs M; Norberg T; Lindgren A; Nordgren H; Holmberg L; Bergh J
    J Natl Cancer Inst; 1996 Feb; 88(3-4):173-82. PubMed ID: 8632491
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Interpretation of P53 Immunohistochemistry in Endometrial Carcinomas: Toward Increased Reproducibility.
    Köbel M; Ronnett BM; Singh N; Soslow RA; Gilks CB; McCluggage WG
    Int J Gynecol Pathol; 2019 Jan; 38 Suppl 1(Iss 1 Suppl 1):S123-S131. PubMed ID: 29517499
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prediction of TP53 mutations by p53 immunohistochemistry and their prognostic significance in gastric cancer.
    Hwang HJ; Nam SK; Park H; Park Y; Koh J; Na HY; Kwak Y; Kim WH; Lee HS
    J Pathol Transl Med; 2020 Sep; 54(5):378-386. PubMed ID: 32601264
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study.
    Leslie KK; Filiaci VL; Mallen AR; Thiel KW; Devor EJ; Moxley K; Richardson D; Mutch D; Secord AA; Tewari KS; McDonald ME; Mathews C; Cosgrove C; Dewdney S; Casablanca Y; Jackson A; Rose PG; Zhou X; McHale M; Lankes H; Levine DA; Aghajanian C
    Gynecol Oncol; 2021 Apr; 161(1):113-121. PubMed ID: 33541735
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunohistochemical correlates of TP53 somatic mutations in cancer.
    Murnyák B; Hortobágyi T
    Oncotarget; 2016 Oct; 7(40):64910-64920. PubMed ID: 27626311
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Diagnostic accuracy of p53 immunohistochemistry as surrogate of TP53 sequencing in endometrial cancer.
    Raffone A; Travaglino A; Cerbone M; De Luca C; Russo D; Di Maio A; De Marco M; Turco MC; Insabato L; Zullo F
    Pathol Res Pract; 2020 Aug; 216(8):153025. PubMed ID: 32703491
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Harmonized molecular classification; assessment of a single-test ProMisE NGS tool.
    Jamieson A; McConechy MK; Lum A; Leung S; Thompson EF; Senz J; Talhouk A; Huntsman DG; Bashashati A; Gilks CB; McAlpine JN
    Gynecol Oncol; 2023 Aug; 175():45-52. PubMed ID: 37321155
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Correlation of genetic and immunodetection of TP53 mutations in malignant and benign prostate tissues.
    Wertz IE; Deitch AD; Gumerlock PH; Gandour-Edwards R; Chi SG; de Vere White RW
    Hum Pathol; 1996 Jun; 27(6):573-80. PubMed ID: 8666367
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinicopathologic analysis of low-stage sporadic ovarian carcinomas: a reappraisal.
    Karamurzin Y; Leitao MM; Soslow RA
    Am J Surg Pathol; 2013 Mar; 37(3):356-67. PubMed ID: 23282975
    [TBL] [Abstract][Full Text] [Related]  

  • 60. p53 Immunohistochemistry Patterns Are Surrogate Biomarkers for
    Li J; Wang J; Su D; Nie X; Liu Y; Teng L; Pang J; Wu H; Liang Z
    Gastroenterol Res Pract; 2021; 2021():2510195. PubMed ID: 34956360
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.